

## Evaluation of von Willebrand Factor levels In Sickle Cell Patients Attending Babcock University Teaching Hospital

### ABSTRACT

**Introduction** von Willebrand Factor (VWF) plays a vital role in platelet aggregation. The unusually large VWF multimers mediate the adhesion of sickle red blood cell (RBC) to endothelial cells and contribute to vaso-occlusive episodes

**Objective** The aim of this study was to determine if there is a correlation between VWF and disease severity in sickle cell Disease.

**Methods** The Babcock University Health Research Ethical committee approved the study. Fifty (50) subjects and 13 controls were recruited into this cross-sectional study. 22 patients presented during steady state while 28 patients presented during vaso-occlusive crisis. Five (5) ml of venous blood was collected. 2 ml was transferred into an Ethylene Diamine Tetra Acetic Acid (EDTA K3) bottle at a concentration of 1.2 mg of anhydrous salt per ml of blood. This was used for blood counts. Three ml of blood was added into 3.2% trisodium citrate in 5% HEPES at a concentration of 9 parts of blood to 1 part of the anticoagulant for the measurement of VWF: Ag level.

**Results** The mean values of VWF in crisis state ( $143.8 \pm 28.00$ ) and steady state ( $105.68 \pm 21.43$ ) were higher than that of the control ( $78.30 \pm 28.10$ ). There was a significant difference in platelet ( $p < 0.000$ ) count among the groups: crisis state has the highest mean value ( $370.64 \pm 128.78$ ), followed by the steady state ( $333.04 \pm 120.47$ ), and the control group ( $221.23 \pm 91.34$ ).

**Conclusion** Severity of sickle cell disease increases with elevation of VWF level in the plasma of patients in crisis state than those in the steady state. This is as a result of the contribution of VWF and the platelets in the formation of microthrombi.

**Keywords:** von Willebrand Factor, Sickle cell, Steady state, Crisis state & Vaso-occlusion

### Introduction

Sickle cell disease (SCD) is an inherited autosomal disorder of the beta-globin chain of haemoglobin, characterized by haemolytic anaemia, intermittent episodes of vascular occlusion that can cause both acute and chronic pain, an increased susceptibility to infections and some organ damage [1]. Haemoglobin is a tetrameric protein which is composed of two pairs of globin chains. A normal adult red blood cell contains mainly adult haemoglobin ( $\alpha_2\beta_2$ ), along with small amounts of A2 haemoglobin ( $\alpha_2\delta_2$ ) and fetal haemoglobin ( $\alpha_2\gamma_2$ ). Sickle cell anaemia is caused by substitution in the sixth position of beta-globin chain which

leads to the replacement of glutamate with valine. The abnormal physiochemical properties of the resulting sickle haemoglobin are responsible for the disease. The underlying pathology of much of these complications is the recurrent occurrence of vaso-occlusion due to micro-thrombi formation resulting in organ ischemia<sup>[2]</sup>. Although the clinical manifestations of the disease are quite heterogeneous, periodic vaso-occlusive crises, and chronic intravascular haemolysis are common in SCD patients<sup>[3]</sup>

Africa has 70% of the world's annual figure of 300,000 affected new births of SCD<sup>[4]</sup>. Nigeria has a population of 112 million with an annual growth rate of 3.2%. About 25% of adults throughout the country have the sickle cell trait (AS) while Hb C trait is largely confined to the south-western Nigeria, where it occurs in about 6% while the homozygous state is found in about 3% of the population<sup>[5]</sup>. However, the prevalence of SCD in Ibadan, Oyo State, is 8.2%<sup>[4]</sup>

Von Willebrand factor (VWF) mediates initial platelet adhesion to the sub-endothelium after vascular injury. VWF is released in plasma due to the inflammatory process induced by the adhesion of sickled red blood cells to the endothelium.<sup>[6]</sup> Adhesion of platelets to the adherent sickled cells and their activation will release more VWF.

Von willebrand factor parameter assessment though not included by National guidelines for the control and management of sickle cell disease, plays a major role in monitoring conditions like thrombosis, occlusive crises, hemolysis and organ ischemia.

## **METHOD**

### ***Ethical consideration/informed consent.***

Ethical approval was obtained from Babcock University Health Research Ethics Committee (BUHREC 172/17) and the patients gave their consent before sampling in accordance with the declarations of Helsinki.

### ***Subjects***

Sickle cell patients who attended the haematology out-patient clinic, those present at the emergency room of the hospital and those on admission at the medical ward of Babcock University Teaching Hospital were recruited into the study. Apparently healthy, age and sex-matched individuals with HbAA were recruited as control. Patients who received blood transfusion less than 6 weeks ago were excluded. Sixty-three (63) were enrolled into the study. This was a cross sectional study. Participants were grouped as per crisis state and stable state. Structured questionnaire and laboratory data were used to enrol participants who meet the inclusion criteria. The sample size for the study was calculated using the following formula<sup>[7,8]</sup>:  $n = \frac{Z^2 \times P(1-P)}{d^2}$

where  $n$  = minimum sample size,  $Z$  = standard normal variance = 1.96 at a 95% confidence interval,  $d$  = absolute SE = 0.05, and  $p$  = prevalence of SCD = 8.2%.

### ***Statistical analysis***

The Statistical package for Social Science (SPSS) version 21.0 software was used for data analysis. Data obtained were presented using tables. One way analysis of variance (ANOVA) and Independent Student T-test were performed where appropriate

81 **Sample collection**

82 Five (5) ml of venous blood was collected. 2 ml was transferred into an Ethylene Diamine  
83 Tetra Acetic Acid (EDTA K3) bottle at a concentration of 1.2 mg of anhydrous salt per ml of  
84 blood. This was used for blood counts. Three ml of blood was added into 3.2% trisodium  
85 citrate in 5% HEPES at a concentration of 9 parts of blood to 1 part of the anticoagulant for  
86 the measurement of VWF: Ag level.

87 **Full Blood Count**

88 The full blood count was performed using an automated haematology analyzer Abacus 5,  
89 according to the manufactures instructions.

90

91 **Von Willebrand Factor (VWF) Antigen**

92 Von Willebrand's factor antigen, VWF: Ag level in plasma was measured using commercial  
93 ELISA kits from Diagnostic Automation according to the manufacturer's instructions.

94 **Results**

95 Sixty three (63) subjects participated in the study, which included fifty (50) sickle cell  
96 patients HbSS and thirteen (13) apparently healthy individuals HbAA.

97

98 **TABLE I The Sociodemographic data of the test subjects**

| VARIABLE                  | FREQUENCY | PERCENT |
|---------------------------|-----------|---------|
| <b>Gender</b>             |           |         |
| Female                    | 26        | 52.0    |
| Male                      | 24        | 48.0    |
| <b>Age</b>                |           |         |
| 16-20                     | 26        | 52.0    |
| 21-25                     | 19        | 38.0    |
| 26-30                     | 0         | 0       |
| 31-35                     | 2         | 4.0     |
| 36 and above              | 3         | 6.0     |
| <b>Hb type</b>            |           |         |
| sc                        | 3         | 6.0     |
| ss                        | 47        | 94.0    |
| <b>Level of Education</b> |           |         |
| Secondary                 | 1         | 2.0     |
| Bachelor's degree         | 49        | 98.0    |
| <b>Occupation</b>         |           |         |
| Student                   | 46        | 92.0    |
| Civil servant             | 4         | 8.0     |
| <b>Marital status</b>     |           |         |
| Single                    | 47        | 94.0    |
| Married                   | 3         | 6.0     |

99

100 **Table II: Shows The Medical History of The Test Subjects and Their Attitude Towards**  
101 **Routine Clinics and Routine Medications.**

| Variable                     | Frequency | percent |      |      |
|------------------------------|-----------|---------|------|------|
| <b>Routine clinic</b>        | Yes 42    | No 8    | 84.0 | 16.0 |
| <b>On routine medication</b> | 49        | 1       | 98   | 2    |
| <b>Hospital</b>              | 45        | 5       | 90.0 | 10.0 |

|                                |                     |                     |              |           |      |      |      |      |
|--------------------------------|---------------------|---------------------|--------------|-----------|------|------|------|------|
| <b>admissions</b>              |                     |                     |              |           |      |      |      |      |
| <b>transfusions</b>            | 23                  |                     |              | 27        | 46.0 |      | 54.0 |      |
| <b>Steady PCV</b>              | 31                  |                     |              | 19        | 62.0 |      | 38.0 |      |
| <b>How often on medication</b> | Daily /48           |                     |              | Weekly/ 1 | 96   |      | 2    |      |
| <b>With Leg Ulcer</b>          | 50                  |                     |              |           | 100  |      |      |      |
| <b>With Stroke</b>             | 50                  |                     |              |           | 100  |      |      |      |
| <b>Clinic attendance</b>       | ≤2x/yr              | ≤ 4x/yr             | ≤ 7x/        | ≥ 8x/yr   |      |      |      |      |
|                                | 24                  | 13                  | 4            | 4         | 48.0 | 26.0 | 8.0  | 8.0  |
| <b>Admissions /yr</b>          | 30                  | 14                  | 1            | 1         | 60.0 | 26.0 | 2.0  | 2.0  |
| <b>Painful crises</b>          | 35                  | 11                  | 2            | 2         | 70.0 | 22.0 | 4.0  | 4.0  |
| <b>supplements</b>             | Ciklavit/5          | Discovite/5         | Others/50    |           | 10.0 | 10.0 | 100  |      |
| <b>Routine Medications</b>     | Folic acid/44       | Multivite/6         | Paludrine/28 | Others/8  | 88.0 | 12.0 | 56.0 | 16.0 |
| <b>PCV range</b>               | 18-20%              | 21-23%              | 24-26%       | ≥27%      |      |      |      |      |
|                                | 6                   | 27                  | 8            | 3         | 12.0 | 54.0 | 16   | 6.0  |
| <b>Management of Crisis</b>    | Self medication /19 | Hospitalization /36 | Prayer/9     |           | 38.0 | 72.0 | 18.0 |      |

Out of the 50 test participants 42 attend the routine clinic, 48% attend routine clinic 1-2 times per year, with 98% on routine medication. The mostly used drug was folic acid with 88% followed by paludrine with 56% and the drug was taken daily by 96% of the subjects. 70% had painful crisis at least 1-3 times per year and 22% 4-6 times per year. 38% of the subjects handled their crisis by self-medication, 72% hospital and 18% through prayers. 45 subjects have been admitted in the last 1 year while 5 had never been admitted in the last one year. The medical history in table II, shows that 60% of the subjects have been admitted about 1-2 times in the last 1 year and 26% had been admitted about 2-4 times. 46% have been transfused while 54% had not been transfused in the last 1 year, with 40% of the population transfused with about 1-2 units of blood. 16% Of this population take supplement with 10% taking ciklavit and 10% taking discovite. All 50 subjects have never had leg ulcer or stroke. 62% of the subject knew their steady pcv, 56% of the population had a pcv within the range of 21-30%.

**Table III Comparisons of Mean Values of Analyzed Parameters Between crisis Period, Steady State and Controls**

| Parameters       | Steady state<br>N=22 | Crisis<br>N=28 | Control<br>N=13 | P-value |
|------------------|----------------------|----------------|-----------------|---------|
| <b>MCV(fl)</b>   | 84.16±7.70           | 83.60±6.00     | 86.74±5.12      | 0.349   |
| <b>MCH(pg)</b>   | 29.70±3.36           | 29.32±2.77     | 27.72±2.51      | 0.149   |
| <b>MCHC(g/l)</b> | 35.30±1.54           | 34.96±1.94     | 31.88±1.43      | 0.000*  |

|                                   |               |               |              |        |
|-----------------------------------|---------------|---------------|--------------|--------|
| <b>PCV (%)</b>                    | 23.07±5.33    | 21.58±3.92    | 32.98±1.58   | 0.000* |
| <b>HB(g/l)</b>                    | 8.09±1.74     | 7.54±1.23     | 10.48±0.48   | 0.000* |
| <b>WBCx10<sup>9/l</sup></b>       | 11.68±3.30    | 17.13±5.70    | 5.53±1.18    | 0.000* |
| <b>PLATELET x10<sup>9/l</sup></b> | 333.04±120.47 | 370.64±128.73 | 221.23±91.34 | 0.002* |
| <b>ANC</b>                        | 5.00±2.11     | 6.52±3.74     | 3.81±0.31    | 0.015* |
| <b>ALC</b>                        | 13.06±17.59   | 14.80±16.84   | 2.56±0.60    | 0.060  |
| <b>RBCx10<sup>12/l</sup></b>      | 2.77±0.77     | 2.61±0.59     | 2.62±0.92    | 0.718  |
| <b>VWF:Ag(%)</b>                  | 105.68±21.43  | 143.82±28.00  | 78.30±28.10  | 0.000* |

**\*statistically significant p<0.05 using one-way ANOVA.** RBC: Red Blood Cell MCH: Mean cell haemoglobin MCV: Mean cell volume MCHC: Mean cell haemoglobin concentration ANC: Absolute neutrophil count ALC: Absolute lymphocyte count PCV: Packed cell volume VWF: Ag: von Willebrand Factor Antigen

**Table IV comparisons of mean values of analyzed parameters between the crisis state and steady state**

| PARAMETERS                       | STEADY<br>N=22 | CRISIS<br>N=28 | P-VALUE |
|----------------------------------|----------------|----------------|---------|
| <b>MCV(fl)</b>                   | 84.16±7.70     | 83.60±6.00     | 0.777   |
| <b>MCH(pg)</b>                   | 29.70±3.36     | 29.32±2.77     | 0.671   |
| <b>MCHC(g/l)</b>                 | 35.30±1.54     | 34.96±1.94     | 0.488   |
| <b>PCV (%)</b>                   | 23.07±5.33     | 21.58±3.92     | 0.282   |
| <b>HB(g/l)</b>                   | 8.09±1.74      | 7.54±1.23      | 0.219   |
| <b>WBCx10<sup>9/l</sup></b>      | 11.68±3.30     | 17.13±5.70     | 0.000*  |
| <b>PLATELETx10<sup>9/l</sup></b> | 333.04±120.47  | 370.64±128.73  | 0.293   |
| <b>ANC</b>                       | 5.00±2.11      | 6.52±3.74      | 0.078   |
| <b>ALC</b>                       | 13.06±17.59    | 14.80±16.84    | 0.726   |
| <b>RBCx10<sup>12/l</sup></b>     | 2.77±0.77      | 2.61±0.59      | 0.430   |
| <b>VWF: Ag (%)</b>               | 105.68±21.43   | 143.82±28.00   | 0.000*  |

**\*statistically significant p<0.05, using t-test** RBC: Red Blood Cell MCH: Mean cell haemoglobin MCV: Mean cell volume MCHC: Mean cell haemoglobin concentration ANC: Absolute neutrophil count ALC: Absolute lymphocyte count PCV: Packed cell volume VWF: Ag: von Willebrand Factor Antigen

**Table V Pearson's correlation between von willebrand Ag and Haematological parameters**

| Parameters       | R-value  | P-value |
|------------------|----------|---------|
| <b>MCV(fl)</b>   | 0.021    | 0.871   |
| <b>MCH(pg)</b>   | 0.244    | 0.054   |
| <b>MCHC(g/l)</b> | 0.345**  | 0.006   |
| <b>PCV(%)</b>    | -0.592** | 0.000   |
| <b>HB(g/l)</b>   | -0.583** | 0.000   |

|                                  |         |       |
|----------------------------------|---------|-------|
| <b>WBCx10<sup>9/l</sup></b>      | 0.541** | 0.000 |
| <b>PLATELETx10<sup>9/l</sup></b> | 0.303*  | 0.016 |
| <b>ANC</b>                       | 0.215   | 0.090 |
| <b>ALC</b>                       | 0.144   | 0.259 |
| <b>RBCx10<sup>12/l</sup></b>     | -0.234  | 0.065 |

\*Statistically Significant at P <0.05. RBC: Red Blood Cell MCH: Mean cell haemoglobin MCV: Mean cell volume MCHC: Mean cell haemoglobin concentration ANC: Absolute neutrophil count ALC: Absolute lymphocyte count PCV: Packed cell volume

## DISCUSSION

Patients with SCD had higher levels of VWF when compared to the controls, with highest mean value in the crisis state (143.82±28.00) and steady state (105.68±21.43). This was in agreement with results reported by [9, 1, 10]. In the process of adhesion of sickle cells to the endothelium there is activation of the endothelium and such activated endothelium will become a source of VWF [11]. This mechanism has also been correlated to the degree of SSRBCs adhesion to the endothelium [12]. The release of these VWF from the endothelial cells, leads to adhesion of more sickled erythrocytes to the endothelium. with the eventual reduction of the lumen of the vessels high shear rate at this site are creating [13]. On the contrary, [9] did not observe any significant difference in the mean VWF of both states (P=0.479). Their study was also able to establish a significant positive correlation between VWF and the severity of the disease, while assigning scores to mark such severe conditions. Furthermore, the mean value for platelet level was observed to be significantly higher in sickle cell patients (crisis (370.64±128.78) and steady state (333.04±120.47)) when compare to control (221.23±91.34) which was in agreement with the result of [9]. The increase in platelet will also aid in the adhesion process. This adhesion of platelets to the adherent sickle cells and their activation will release more VWF. [14]

High levels of VWF mediate the adhesion of sickled RBC to endothelial cells and contributes to vaso-occlusive episodes. These vasoocclusive crises may occur when endothelial cells are greatly stimulated to release the content of their Weibel-Palade bodies [15].

Sickle red cells, in contrast to normal red blood cells, may have receptors for VWF on their surface because they are relatively younger cells, or because of alterations in their membrane structure induced by cycles of HbS polymerization-depolymerization in conjunction with shear forces in the blood [16]

In SCD VWF antigen levels often increases in times of crises, suggesting that endothelial cell stimulation or damage occurred [17]. We therefore propose that this mechanism of endothelial cell damage will lead to the exposure of the sub endothelial structure, with eventual activation of platelets, and the formation of micro thrombi.

## CONCLUSION

Severity of sickle cell disease increases with elevation of VWF level in crisis state than those in the steady state, this contributes to the vasoocclusive episode

## REFERENCES

1. Nawal, E.O. Correlation between the plasma level of von willebrand factor and the severity of sickle cell disease in Sudanese patients. University of Khartoum Faculty of Medicine (2004).
2. Robbins, Kumar, and Cotran, M. Von Willebrand Factor. Textbook of basic pathology, 6<sup>th</sup> edition. (2005). Philadelphia, pa: Elsevier Saunders.
3. Zhou, Z. Hemoglobin blocks von willibrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. *Thromb Haemost* (2009). **101**(9):1070–1077.
- 4 Akodu, S., Diaku, A., and Njokanma, O. Age and Diagnosis of Sickle Cell Anaemia in Lagos, Nigeria. *Mediterr J. of haematol and infec. diseases*. (2013). **5**(1) 1-15.
- 5 Akinyanju, O. Issues in the Management and Control of Sickle Cell Disorder. *Archives of Ibadan Medicine* (2001). **2**(3):37–41
6. Ikeda, Y., Handa, M. and Kawanok, The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. *J Clin Invest*. (2001). **87**(4): 1234 -1240
7. Araoye MO. Research methodology with statistics for health and social sciences. In: Subject selection, Nathadex publishers, Ilorin 2004; 115-120
8. Jeremiah ZA, Oburu JE. Survey of platelet glycoprotein specific antibodies and HLA class 1 antibodies in a cross section of Nigerian multiparous women. *Int J Blood Transfus Immunohematol* 2011; **1**:7–11.
9. Nawal, E.O., Maria, M. H. S. and Abdelrahim, O. M. Plasma level of von Willebrand factor: an indicator of severity in sickle cell disease. *Sudan Journal of Medical Sciences* (2009) vol. 4(2): <http://dx.doi.org/10.4314/sjms.v4i2.44897>
10. Richardson, S.G., Mathews, K.B. and Stuart, J. Serial changes in coagulation and viscosity during sickle cell crisis. *Br J Haematol* (2002). **41**(9):95-103.
11. Sweerlick, R. A., Eckman, J. R., Kumar, A., Jeitler, M. and Wick, T. M.  $\alpha 4\beta 1$  integrin expression on Sickle erythrocyte: Vascular cell adhesion molecule–1-dependent binding to endothelium. *J. Biol. Chem*. (2001). **82**(5):18-91.
12. Kaul, D.K., Nagel, R.L., Chen, DSickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vaso-occlusion. *J.Blood* . (2003). **81**(9), 2429-2438.
13. Brittaia, H.A., Eckman, J.R., Swerlick, R.A., Howard, R.J. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to microvascular endothelium under physiologic flow: A potential role of platelet activation in sickle cell (2013).
14. Nichols, T.C., Bellinger, D.A., Reddick, R.L Role of von wellibrand factor in arterial thrombosis. Studies in normal and von wellibrand disease. *Circulation* (1991). **83**(4) 56-64.

- 202 15. Frangos, J., Moake, and L. V., McIntire, K. Evidence for an endothelial cell-dependent  
203 VWF processing activity in plasma. *Clin. Res.* (2006). **34**(3):656
- 204 16. Moake, J.L., Turner, N.A., Stathopoulos, N.A., Nolasco, L. H. and Hellums, J. D.  
205 Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large  
206 VWF forms derived from endothelial cells in shear stress-induced platelet aggregation. *J.*  
207 *Clin. Invest.* (2006). **78**(20):1456-1461
- 208 17. Mackie, I., H., Bull, N. and M. Brozovic. Altered factor VIII complexes in sickle cell  
209 disease *Br. J. Haematol.* (2000). **46**(8):499-502.